UK business Vertellus Biomaterials and Sorin Group Italia Srl have signed a long-term licence and supply agreement, to run until the end of 2012.
The deal covers the supply of phosphorylcholine (PC) technology by Vertellus to Sorin for coating cardiopulmonary bypass equipment used during open heart surgery.
PC technology refers to a portfolio of biocompatible polymers containing phosphorylcholine. These materials have been shown to reduce biofouling and to improve the performance of medical devices.
US company Vertellus Specialties Inc, parent company of the Biomaterials business, licensed the technology from Biocompatibles UK Ltd in 2006 and set up the biomaterials business unit in Herriard, Hampshire, UK.
PC inhibits the process of rejection by the body by binding water tightly around itself, forming a barrier between the body and the coated material.
This has the effect of: decreasing protein and lipid deposition; discouraging adhesion of bacteria and other microorganisms; minimizing clot formation; reducing inflammatory response; and diminishing fibrous capsule generation.
The PC technology materials have been used in many applications, including contact lenses, coronary stents and urological catheters.
For further information, contact: Dr Mike Driver, Business Director, Vertellus Biomaterials, Unit 3 The Bullpens, Manor Court, Herriard, Basingstoke, Hampshire RG25 2PH, UK; tel: +44-1256-381951; fax: +44-1256-381274; Internet: www.vertellus.com; or: www. pcbiomaterials.com; or contact: Marco Chiado Piat, Vice President, Corporate Development, Sorin SpA, via Benigno Crespi 17, 20159 Milano, Italy; tel: +39-02-69969711-509; E-mail: marco.chiadopiat@sorin.com; Internet: www.sorin.com
No comments:
Post a Comment